SKWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Skyward Specialty Insurance Group Inc (SKWD) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company's financial performance is impressive, the technical indicators suggest a bearish trend, and there are no significant positive catalysts or trading signals to support an immediate purchase. Holding off for a better entry point or further positive developments is recommended.
The technical indicators show a bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 46.183, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 43.388, with key resistance at 45.592 and support at 41.184. The stock has a 60% chance of declining in the short term (-0.32% next day, -1.17% next week, -3.55% next month).
The company reported strong financial performance in Q4 2025, with a 22.06% YoY revenue increase and a 200.08% YoY net income growth. Analysts have maintained positive ratings, with Keefe Bruyette recently raising the price target to $70 and Barclays highlighting the company's attractive business mix and accretive acquisition of Apollo Group Holdings.
The technical indicators suggest a bearish trend, and options data indicates a higher open interest in puts compared to calls (Put-Call Ratio of 1.41). The lack of recent news, congress trading data, or significant insider/hedge fund activity further limits positive momentum. Piper Sandler also lowered its price target to $55, citing a conservative valuation approach in a soft market.
In Q4 2025, Skyward Specialty Insurance reported revenue of $380.98M, up 22.06% YoY. Net income grew significantly to $43.23M, up 200.08% YoY, and EPS increased to 1.03, up 194.29% YoY. The company demonstrated strong growth trends, but gross margin remained unchanged.
Analysts are generally positive on SKWD. Keefe Bruyette raised its price target to $70, maintaining an Outperform rating. Barclays reinstated coverage with an Overweight rating and a $63 price target, citing the company's attractive business mix and acquisition synergies. However, Piper Sandler lowered its price target to $55, reflecting a more conservative valuation approach in the current market environment.
